| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Accommodation and Health Costs of Deinstitutionalized People with Mental Illness Living in Residential Services in Brazil
|
Razzouk, Denise
|
|
2018
|
|
1 |
p. 31-42
|
artikel
|
| 2 |
Acknowledgement to Referees
|
|
|
|
|
1 |
p. 1-3
|
artikel
|
| 3 |
Acknowledgement to Referees
|
|
|
|
|
1 |
p. 1-2
|
artikel
|
| 4 |
Acknowledgement to Referees
|
|
|
|
|
1 |
p. 1-3
|
artikel
|
| 5 |
A Cost-Effectiveness Analysis Comparing the VivaSight Double-Lumen Tube and a Conventional Double-Lumen Tube in Adult Patients Undergoing Thoracic Surgery Involving One-Lung Ventilation
|
Larsen, Sara
|
|
|
|
1 |
p. 159-169
|
artikel
|
| 6 |
An Evaluation of Diagnosis-Related Group (DRG) Implementation Focused on Cancer DRGs in Greek Public Hospitals
|
Panagiotopoulos, Panos
|
|
|
|
1 |
p. 61-69
|
artikel
|
| 7 |
An Exploratory Study of Long-Term Publicly Waitlisted Bariatric Surgery Patients’ Quality of Life Before and 1 Year After Bariatric Surgery, and Considerations for Healthcare Planners
|
Campbell, Julie A.
|
|
2017
|
|
1 |
p. 63-76
|
artikel
|
| 8 |
Application of Discrete-Choice Experiment Methods in Tobacco Control: A Systematic Review
|
Regmi, Kabindra
|
|
2017
|
|
1 |
p. 5-17
|
artikel
|
| 9 |
Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
|
Felizzi, F.
|
|
|
|
1 |
p. 37-46
|
artikel
|
| 10 |
A Real-World Assessment of Outcomes, Health Resource Utilization, and Costs Associated with Cerebral Edema in US Patients with Large Hemispheric Infarction
|
Tsao, Nicole
|
|
|
|
1 |
p. 63-72
|
artikel
|
| 11 |
A Single-Center Cost Analysis of Treating Primary and Metastatic Brain Cancers with Either Brain Laser Interstitial Thermal Therapy (LITT) or Craniotomy
|
Leuthardt, Eric C.
|
|
2016
|
|
1 |
p. 53-63
|
artikel
|
| 12 |
Assessing the Impact of Growth Hormone Deficiency (GHD) in Adults: Interpreting Change of the Treatment-Related Impact Measure—Adult Growth Hormone Deficiency (TRIM-AGHD)
|
Brod, Meryl
|
|
2018
|
|
1 |
p. 71-80
|
artikel
|
| 13 |
Assessing Variation in the Cost of Palivizumab for Respiratory Syncytial Virus Prevention in Preterm Infants
|
Shahabi, Ahva
|
|
2017
|
|
1 |
p. 53-61
|
artikel
|
| 14 |
A Systematic Review of Cost-Effectiveness Analyses for Hepatocellular Carcinoma Treatment
|
Yuen, Sydney C.
|
|
|
|
1 |
p. 9-19
|
artikel
|
| 15 |
A Systematic Review of Time and Resource Use Costs of Subcutaneous Versus Intravenous Administration of Oncology Biologics in a Hospital Setting
|
McCloskey, Conor
|
|
|
|
1 |
p. 3-36
|
artikel
|
| 16 |
Authors’ Reply to Holko: “Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review”
|
Akpinar, Ilke
|
|
2017
|
|
1 |
p. 71
|
artikel
|
| 17 |
Buccal Midazolam Solution for the Management of Prolonged Acute Convulsive Seizures: A Cost Analysis
|
Ludwig, Catherine
|
|
|
|
1 |
p. 171-179
|
artikel
|
| 18 |
Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
|
Lee, D.
|
|
2018
|
|
1 |
p. 43-54
|
artikel
|
| 19 |
Comment on: “Forecasting Pharmaceutical Prices for Economic Evaluations When There is No Market: A Review”
|
Holko, Przemysław
|
|
2016
|
|
1 |
p. 69-70
|
artikel
|
| 20 |
Communal Sharing and the Provision of Low-Volume High-Cost Health Services: Results of a Survey
|
Richardson, Jeff
|
|
2016
|
|
1 |
p. 13-23
|
artikel
|
| 21 |
Comparison of Disease-Modifying Therapies for the Management of Multiple Sclerosis: Analysis of Healthcare Resource Utilization and Relapse Rates from US Insurance Claims Data
|
Nicholas, Jacqueline
|
|
2017
|
|
1 |
p. 31-41
|
artikel
|
| 22 |
Conducting a Time Trade-Off Study Alongside a Clinical Trial: A Case Study and Recommendations
|
Shen, Jing
|
|
2018
|
|
1 |
p. 5-20
|
artikel
|
| 23 |
Continuous Monitoring of Respiratory Rate with Wearable Sensor in Patients Admitted to Hospital with Pneumonia Compared with Intermittent Nurse-Led Monitoring in the United Kingdom: A Cost-Utility Analysis
|
Javanbakht, Mehdi
|
|
|
|
1 |
p. 73-83
|
artikel
|
| 24 |
Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial
|
Felizzi, F.
|
|
|
|
1 |
p. 47-48
|
artikel
|
| 25 |
Correction to: Can We Accurately Predict Cost Effectiveness Without Access to Overall Survival Data? The Case Study of Nivolumab in Combination with Ipilimumab for the Treatment of Patients with Advanced Melanoma in England
|
Lee, D.
|
|
2018
|
|
1 |
p. 127
|
artikel
|
| 26 |
Correction to: Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
|
Shah, Karan K.
|
|
|
|
1 |
p. 63
|
artikel
|
| 27 |
Cost-Effectiveness Analysis of Recombinant Factor VIII Fc-Fusion Protein (rFVIIIFc) for the Treatment of Severe Hemophilia A in Italy Incorporating Real-World Dosing and Joint Health Data
|
Bullement, Ash
|
|
|
|
1 |
p. 133-142
|
artikel
|
| 28 |
Cost-Effectiveness Analysis of the Treatment Strategies with or without Opioid Medications in Surgery-Eligible Patients with Osteoarthritis in Japan
|
Takura, Tomoyuki
|
|
|
|
1 |
p. 33-45
|
artikel
|
| 29 |
Cost Effectiveness of a Cultural Physical Activity Intervention to Reduce Blood Pressure Among Native Hawaiians with Hypertension
|
Railey, Ashley F.
|
|
|
|
1 |
p. 85-94
|
artikel
|
| 30 |
Cost Effectiveness of Ambulatory Blood Pressure Monitoring Compared with Home or Clinic Blood Pressure Monitoring for Diagnosing Hypertension in Australia
|
Shah, Karan K.
|
|
|
|
1 |
p. 49-62
|
artikel
|
| 31 |
Cost-Effectiveness of Inotuzumab Ozogamicin Compared to Standard of Care Chemotherapy for Treating Relapsed or Refractory Acute Lymphoblastic Leukaemia Patients in Norway and Sweden
|
van Oostrum, I.
|
|
|
|
1 |
p. 47-62
|
artikel
|
| 32 |
Cost Effectiveness of Long-Term Incobotulinumtoxin-A Treatment in the Management of Post-stroke Spasticity of the Upper Limb from the Australian Payer Perspective
|
Makino, Koji
|
|
2018
|
|
1 |
p. 93-102
|
artikel
|
| 33 |
Cost Effectiveness of Mirabegron Compared with Antimuscarinic Agents for the Treatment of Adults with Overactive Bladder in Colombia
|
Parise, Hélène
|
|
|
|
1 |
p. 79-90
|
artikel
|
| 34 |
Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland
|
Favre-Bulle, Andrea
|
|
|
|
1 |
p. 91-101
|
artikel
|
| 35 |
Cost-Effectiveness of Three Alternative Boosted Protease Inhibitor-Based Second-Line Regimens in HIV-Infected Patients in West and Central Africa
|
Boyer, S.
|
|
|
|
1 |
p. 45-60
|
artikel
|
| 36 |
Cost of Patients with Alzheimer’s Disease in Spain According to Disease Severity
|
Gómez Maldonado, Laura
|
|
|
|
1 |
p. 103-114
|
artikel
|
| 37 |
Costs and Extra Length of Stay because of Neonatal Bloodstream Infection at a Teaching Hospital in Ghana
|
Fenny, Ama Pokuaa
|
|
|
|
1 |
p. 111-120
|
artikel
|
| 38 |
Costs of Respiratory Syncytial Virus Hospitalizations in Colombia
|
Buendía, Jefferson Antonio
|
|
|
|
1 |
p. 71-76
|
artikel
|
| 39 |
Developing a Natural History Model for Duchenne Muscular Dystrophy
|
Broomfield, Jonathan
|
|
|
|
1 |
p. 79-89
|
artikel
|
| 40 |
“Don’t Think Twice, It’s All Right”: Using Additional Data to Reduce Uncertainty Regarding Oncologic Drugs Provided Through Managed Access Agreements in England
|
Kang, Jiyeon
|
|
|
|
1 |
p. 77-91
|
artikel
|
| 41 |
Do Rural Residents in China Understand EQ-5D-5L as Intended? Evidence From a Qualitative Study
|
Yang, Fan
|
|
|
|
1 |
p. 101-109
|
artikel
|
| 42 |
Early Cost-Effectiveness Analysis of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer Patients with Limited Peritoneal Carcinomatosis
|
Verbeek, Joost G. E.
|
|
|
|
1 |
p. 119-131
|
artikel
|
| 43 |
Early Cost-Effectiveness and Price Threshold Analyses of Resmetirom: An Investigational Treatment for Management of Nonalcoholic Steatohepatitis
|
Javanbakht, Mehdi
|
|
|
|
1 |
p. 93-110
|
artikel
|
| 44 |
Early Economic Evaluation to Identify the Necessary Test Characteristics of a New Typhoid Test to be Cost Effective in Ghana
|
Frempong, Samuel N.
|
|
|
|
1 |
p. 143-157
|
artikel
|
| 45 |
Economic Analysis of the CADScor System for Ruling Out Coronary Artery Disease in England
|
Javanbakht, Mehdi
|
|
|
|
1 |
p. 123-135
|
artikel
|
| 46 |
Economic Burden of Chronic Obstructive Pulmonary Disease Patients in Malaysia: A Longitudinal Study
|
ur Rehman, Anees
|
|
|
|
1 |
p. 35-44
|
artikel
|
| 47 |
Economic Burden of Delayed Diagnosis in Patients with Pulmonary Arterial Hypertension (PAH)
|
DuBrock, Hilary M.
|
|
|
|
1 |
p. 133-146
|
artikel
|
| 48 |
Economic Evaluation of Bevacizumab for Treatment of Platinum-Resistant Recurrent Ovarian Cancer in Canada
|
Ball, Graeme
|
|
2017
|
|
1 |
p. 19-29
|
artikel
|
| 49 |
Economic Impact of Mirabegron Versus Antimuscarinics for the Treatment of Overactive Bladder in the UK
|
Nazir, Jameel
|
|
2017
|
|
1 |
p. 25-36
|
artikel
|
| 50 |
Economic Model to Evaluate the Cost-Effectiveness of Second-Line Nilotinib Versus Dasatinib for the Treatment of Philadelphia Chromosome-Positive Chronic Myeloid Leukemia (CML-CP) in Italy
|
Bonifacio, Massimiliano
|
|
|
|
1 |
p. 95-104
|
artikel
|
| 51 |
Encorafenib with Binimetinib for the Treatment of Patients with BRAF V600 Mutation-Positive Unresectable or Metastatic Melanoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal
|
Houten, Rachel
|
|
|
|
1 |
p. 13-22
|
artikel
|
| 52 |
Estimating the Economic and Clinical Value of Introducing Ceftazidime/Avibactam into Antimicrobial Practice in Japan: A Dynamic Modelling Study
|
Matsumoto, Tetsuya
|
|
|
|
1 |
p. 65-76
|
artikel
|
| 53 |
Evaluation of the Impact of an Institution-Specific Dofetilide Initiation Protocol on Mean Hospital Length of Stay and Cost for Dofetilide Initiation
|
Kennedy, Steven P.
|
|
2018
|
|
1 |
p. 119-126
|
artikel
|
| 54 |
Exploring the Influence of Health Insurance Plans on Biosimilar Adoption Rates
|
Costin, Jeremy
|
|
|
|
1 |
p. 115-118
|
artikel
|
| 55 |
Fall/Fracture-Related Healthcare Costs and Their Association with Cumulative Anticholinergic Burden in People with Overactive Bladder
|
Lozano-Ortega, Greta
|
|
|
|
1 |
p. 45-55
|
artikel
|
| 56 |
Forecasting Pharmaceutical Prices for Economic Evaluations When There Is No Market: A Review
|
Akpinar, Ilke
|
|
2016
|
|
1 |
p. 65-68
|
artikel
|
| 57 |
Gaining Patient Input on Naming a Novel Patient-Reported Outcome Instrument in Chronic Weight Management
|
Rozjabek, Heather
|
|
|
|
1 |
p. 133-137
|
artikel
|
| 58 |
Healthcare Costs Before and After Diagnosis of Cancer of Unknown Primary Versus Ovarian Cancer in Australia
|
Gordon, Louisa G.
|
|
|
|
1 |
p. 111-120
|
artikel
|
| 59 |
Healthcare, Sickness Absence, and Disability Pension Cost Trajectories in the First 5 Years After Diagnosis with Multiple Sclerosis: A Prospective Register-Based Cohort Study in Sweden
|
Karampampa, Korinna
|
|
|
|
1 |
p. 91-103
|
artikel
|
| 60 |
Healthcare Utilization and Cost Burden of Porphyria in Commercially Insured Adults in the United States
|
Elsaid, Mohamed I.
|
|
|
|
1 |
p. 89-100
|
artikel
|
| 61 |
Health State Utility Data in Cystic Fibrosis: A Systematic Review
|
Mohindru, Bishal
|
|
|
|
1 |
p. 13-25
|
artikel
|
| 62 |
Health Technology Assessment for Policy Making in India: Current Scenario and Way Forward
|
Prinja, Shankar
|
|
2017
|
|
1 |
p. 1-3
|
artikel
|
| 63 |
Hospital Length of Stay for Patients with Severe COVID-19: Implications for Remdesivir’s Value
|
Anderson, Michaela R.
|
|
|
|
1 |
p. 129-131
|
artikel
|
| 64 |
Impact of Plan-Level Access Restrictions on Effectiveness of Biologics Among Patients with Rheumatoid or Psoriatic Arthritis
|
Boytsov, Natalie
|
|
|
|
1 |
p. 105-117
|
artikel
|
| 65 |
Influence of Idiopathic Pulmonary Fibrosis Progression on Healthcare Resource Use
|
Diamantopoulos, Alex
|
|
2018
|
|
1 |
p. 81-91
|
artikel
|
| 66 |
International HTA Experience with Targeted Therapy Approvals for Lung Cancer
|
Maraiki, Fatma
|
|
2018
|
|
1 |
p. 103-117
|
artikel
|
| 67 |
Investigation of Factors Considered by Health Technology Assessment Agencies in Eight Countries
|
Yuasa, Akira
|
|
|
|
1 |
p. 57-69
|
artikel
|
| 68 |
Mapping of the World Health Organization Quality of Life Brief (WHOQOL-BREF) to the EQ-5D-5L in the General Thai Population
|
Kangwanrattanakul, Krittaphas
|
|
|
|
1 |
p. 139-148
|
artikel
|
| 69 |
Mapping the Insomnia Severity Index Instrument to EQ-5D Health State Utilities: A United Kingdom Perspective
|
Chalet, François-Xavier
|
|
|
|
1 |
p. 149-161
|
artikel
|
| 70 |
Medical Costs of Patients with Type 2 Diabetes in a Single Payer System: A Classification and Regression Tree Analysis
|
Rucci, Paola
|
|
|
|
1 |
p. 181-190
|
artikel
|
| 71 |
NICE and the EQ-5D-5L: Ten Years Trouble
|
Sampson, Chris
|
|
|
|
1 |
p. 5-8
|
artikel
|
| 72 |
Patient and Caregiver Health State Utilities in Tuberous Sclerosis Complex
|
Lo, Siu Hing
|
|
|
|
1 |
p. 105-121
|
artikel
|
| 73 |
Population Screening for Hereditary Haemochromatosis in Australia: Construction and Validation of a State-Transition Cost-Effectiveness Model
|
Graaff, Barbara de
|
|
2016
|
|
1 |
p. 37-51
|
artikel
|
| 74 |
Preferences for Living Arrangements in Dementia: A Discrete Choice Experiment
|
Speckemeier, Christian
|
|
|
|
1 |
p. 65-78
|
artikel
|
| 75 |
Productivity Loss and Associated Costs Among Employed Patients Receiving Disease-Modifying Treatment for Multiple Sclerosis
|
Bonafede, Machaon
|
|
|
|
1 |
p. 23-34
|
artikel
|
| 76 |
Psychometric Validation of the Growth Hormone Deficiency–Child Treatment Burden Measure (GHD-CTB) and the Growth Hormone Deficiency–Parent Treatment Burden Measure (GHD-PTB)
|
Brod, Meryl
|
|
|
|
1 |
p. 121-138
|
artikel
|
| 77 |
Public Health Impact and Cost-Effectiveness of Empagliflozin (JARDIANCE®) in the Treatment of Patients with Heart Failure with Preserved Ejection Fraction in France, Based on the EMPEROR-Preserved Clinical Trial
|
Fauchier, Laurent
|
|
|
|
1 |
p. 19-30
|
artikel
|
| 78 |
Real-World Evidence: Bridging Gaps in Evidence to Guide Payer Decisions
|
Roberts, Melissa H.
|
|
|
|
1 |
p. 3-11
|
artikel
|
| 79 |
Reduction of Direct Health Costs Associated with Pertussis Vaccination with Acellular Vaccines in Children Aged 0–9 Years with Pertussis in Catalonia (Spain)
|
Plans-Rubió, Pedro
|
|
2018
|
|
1 |
p. 55-69
|
artikel
|
| 80 |
Registered Reports: Time to Radically Rethink Peer Review in Health Economics
|
Clarke, Philip
|
|
|
|
1 |
p. 1-4
|
artikel
|
| 81 |
Reliability and Validity of the Greek Migraine Disability Assessment (MIDAS) Questionnaire
|
Oikonomidi, Theodora
|
|
2017
|
|
1 |
p. 77-85
|
artikel
|
| 82 |
Return on Investment of Free Colorectal Cancer Screening Tests in a Primarily Rural Uninsured or Underinsured Population in Northeast Texas
|
Orsak, Gabriela
|
|
|
|
1 |
p. 71-77
|
artikel
|
| 83 |
Specialist Palliative Care and Health Care Costs at the End of Life
|
Kenny, Patricia
|
|
|
|
1 |
p. 31-47
|
artikel
|
| 84 |
Symptoms and Dietary Impact in Hypertriglyceridemia-Associated Pancreatitis: Development and Content Validity of Two New Measures
|
Burbridge, Claire
|
|
|
|
1 |
p. 191-201
|
artikel
|
| 85 |
Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights
|
Bartelt-Hofer, Jose
|
|
|
|
1 |
p. 5-12
|
artikel
|
| 86 |
Systematic Review of Economic Evaluations in Primary Open-Angle Glaucoma: Decision Analytic Modeling Insights
|
Bartelt-Hofer, Jose
|
|
|
|
1 |
p. 5-12
|
artikel
|
| 87 |
Systematic Review of Economic Models Used to Compare Techniques for Detecting Peripheral Arterial Disease
|
Moloney, Eoin
|
|
2018
|
|
1 |
p. 21-30
|
artikel
|
| 88 |
The Acceptance of Indirect Treatment Comparison Methods in Oncology by Health Technology Assessment Agencies in England, France, Germany, Italy, and Spain
|
Macabeo, Bérengère
|
|
|
|
1 |
p. 5-18
|
artikel
|
| 89 |
The Health System Costs of Potentially Inappropriate Prescribing: A Population-Based, Retrospective Cohort Study Using Linked Health Administrative Databases in Ontario, Canada
|
Black, Cody D.
|
|
|
|
1 |
p. 27-36
|
artikel
|
| 90 |
The Potential Cost-Effectiveness of HIV Vaccines: A Systematic Review
|
Adamson, Blythe
|
|
2017
|
|
1 |
p. 1-12
|
artikel
|
| 91 |
The Use of Computer Simulation Modeling to Estimate Complications in Patients with Type 2 Diabetes Mellitus: Comparative Validation of the Cornerstone Diabetes Simulation Model
|
Su, Zhuo T.
|
|
|
|
1 |
p. 37-44
|
artikel
|
| 92 |
The Utility of Economic Measures to Quantify the Burden of Tinnitus in Affected Individuals: A Scoping Review
|
Daoud, Elza
|
|
|
|
1 |
p. 21-32
|
artikel
|
| 93 |
The Value of a New Diagnostic Test for Prostate Cancer: A Cost-Utility Analysis in Early Stage of Development
|
Fridhammar, Adam
|
|
|
|
1 |
p. 77-88
|
artikel
|
| 94 |
Trends in Drug Costs and Overall Survival in Patients with Metastatic Non-small Cell Lung Cancer in The Netherlands Diagnosed from 2008 Through 2014
|
Cramer-van der Welle, Christine M.
|
|
|
|
1 |
p. 121-127
|
artikel
|
| 95 |
United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument
|
King, Madeleine T.
|
|
|
|
1 |
p. 49-63
|
artikel
|
| 96 |
US Integrated Delivery Networks Perspective on Economic Burden of Patients with Treatment-Resistant Depression: A Retrospective Matched-Cohort Study
|
Pilon, Dominic
|
|
|
|
1 |
p. 119-131
|
artikel
|
| 97 |
Value Assessment Frameworks in the United States: A Call for Patient Engagement
|
Diaby, Vakaramoko
|
|
2018
|
|
1 |
p. 1-3
|
artikel
|
| 98 |
Want to Improve Public Health Access? Let’s Start with the Basics: Measuring Efficiency Correctly
|
Andrews, Antony
|
|
|
|
1 |
p. 1-2
|
artikel
|
| 99 |
Weighting Health Outcomes by Socioeconomic Position Using Stated Preferences
|
Lal, Anita
|
|
2017
|
|
1 |
p. 43-51
|
artikel
|
Tijdschrift beschrijving